PD-L1 expression was assessed with PD-L1 IHC 22C3 pharmDx assay in studies involving pembrolizumab measuring the PD-L1 expression on tumor cells as well as immune cells which was termed as combined positive score (CPS) (11, 12, 17, 30, 41). Here, CD274 is linked to neoplasm.